| 美国专利重复授权审查标准研究及对我国的启示 |
| |
| 引用本文： | 丁锦希,詹来明. 美国专利重复授权审查标准研究及对我国的启示[J]. 上海医药, 2014, 0(11): 49-53 |
| |
| 作者姓名： | 丁锦希 詹来明 |
| |
| 作者单位： | 中国药科大学医药知识产权研究所,南京211198 |
| |
| 基金项目： | 基金项目：2013年度国家社会科学基金资助项目（No.13BFX120）,项目名称：《TRIPS框架下中国药品试验数据保护制度研究》 |
| |
| 摘 要： | 通过分析美国近期发生的“Lilly vs Teva”生物医药专利重复授权纠纷案，深入研究美国专利重复授权的审查标准，在此基础上讨论我国目前重复授权的审查标准，指出存在的问题及可能带来的一些不利影响。最后结合美国重复授权审查标准，对我国重复授权审查标准的完善提出建议。
|
| 关 键 词： | 抵触申请 重复授权 非显而易见性 审查标准 |
The examination standard of double patenting in the U.S. and its implications on China |
| |
| DING Jinxi,ZHAN Laiming. The examination standard of double patenting in the U.S. and its implications on China[J]. Shanghai Medical & Pharmaceutical Journal, 2014, 0(11): 49-53 |
| |
| Authors: | DING Jinxi ZHAN Laiming |
| |
| Affiliation: | (Pharmaceutical Intellectual Property Research Institute, China Pharmaceutical University, Nanjing 211198, China) |
| |
| Abstract: | The examination standard for double patenting in the U.S. was deeply studied by analyzing the bio-pharmaceutical patent disputes concerning double patenting between Eli Lilly and Teva. On this basis, the examination standard of double patenting in China was discussed and the problems and possible adverse impact were also pointed out. And ifnally, several pieces of reasonable suggestions were proposed so as to complete Chinese examination standard of double patenting based on that in the U.S.. |
| |
| Keywords: | conlficting applications double patenting non-obviousness examination standards |
| 本文献已被 维普 等数据库收录！ |
